AllSci News
LEO Pharma picks up dersimelagon for USD 435m to challenge Scenesse in rare photodermatoses
Denmark-based LEO Pharma has agreed to acquire worldwide rights to dersimelagon, an oral melanocortin 1 receptor (MC1R) agonist for two ultra-rare...
Ingenia Therapeutics lists on KOSDAQ to fund vascular antibody pipeline
Watertown, Massachusetts-based Ingenia Therapeutics, a clinical-stage biotech whose lead ophthalmology antibody is being developed by Merck, began trading...
Amylyx's avexitide cuts hypoglycemic events by 55% in Phase III post-bariatric trial
Avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, met the primary endpoint of the Phase III LUCIDITY trial in post-bariatric...
Antares launches FIH trial of ATX-898 with CDK4/6 breast cancer combos
Antares Therapeutics, Inc. has registered a first-in-human Phase I/II study of ATX-898, an investigational small molecule whose molecular target has not...
Filamon launches first-in-human trial of topical MEK inhibitor in wet AMD
Australia-based Filamon Limited has registered a Phase Ib/IIa first-in-human clinical trial of BETA-TT8 Ophthalmic Gel 3.8%, a topical small-molecule...
Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m
Emeryville, California-based OmniAb (Nasdaq: OABI) has signed a global collaboration and license agreement with Eli Lilly (NYSE: LLY) for a new ion channel...
Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field
Raleigh, North Carolina-based Slate Medicines, Inc. will gain a Nasdaq listing through an all-stock reverse merger with Cambridge, Massachusetts-based...
EyePoint's Duravyu misses wet AMD primary endpoint, hinges on second trial for FDA path
EyePoint Pharmaceuticals (Nasdaq: EYPT) reported topline data from LUGANO, the first of two pivotal Phase III trials evaluating vorolanib (Duravyu)...
Can-Fite's namodenoson boosts gemcitabine potency in pancreatic cancer preclinical models
New preclinical data from Can-Fite BioPharma Ltd. (NYSE American: CANF) show that namodenoson, an oral A3 adenosine receptor (A3AR) agonist, enhances the...
J&J hands C-CAR039 back to AbelZeta amid pivot toward in vivo CAR-T
AbelZeta Pharma reclaimed full global rights to its anti-CD19/CD20 bispecific CAR-T cell therapy prizloncabtagene autoleucel (C-CAR039) from Janssen Biotech...
BioCytics and LIDE Biotech partner to validate immune cell therapies in patient-derived tumor models
Huntersville, North Carolina-based BioCytics, Inc. and Shanghai-based preclinical oncology contract research organization LIDE Biotech have announced a...
Leal Therapeutics raises USD 30m to advance glutaminase inhibitor in schizophrenia
Worcester, Massachusetts-based Leal Therapeutics, Inc. has closed a USD 30 million Series A extension — the second close of its Series A — alongside the...
AstraZeneca drops Phase III volrustomig trial after pembrolizumab challenge fails
AstraZeneca (LSE/STO/NYSE: AZN) is discontinuing the eVOLVE-Lung02 Phase III trial after an Independent Data Monitoring Committee (IDMC) concluded that...
Myeloid cell transplantation rescues Friedreich's ataxia through mitochondrial transfer in mice
Hematopoietic transplantation can rescue neurological and cardiac deficits in a mouse model of Friedreich's ataxia (FA) — not by replacing diseased neurons...
Pitt, Magee-Womens team turns cancer dormancy into a druggable vulnerability
A preclinical study from the University of Pittsburgh and Magee-Womens Research Institute & Foundation identifies a two-drug strategy that selectively kills...
The AllSci Brief
Free, systematic R&D and deal news. Daily.